These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 8053763)

  • 1. [Immunogenicity and tolerability of Haemophilus b-tetanus protein conjugate (PRP-T) in children with sickle cell anemia].
    de Montalembert M; Bégué P; Fritzell B; Houmeau P
    Arch Fr Pediatr; 1993 Dec; 50(10):863-6. PubMed ID: 8053763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of two Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccines (PRP-T) given with diphtheria-tetanus-pertussis vaccine to young Papua New Guinean children.
    Lehmann D; Kakazo M; Saleu G; Taime J; Javati A; Namuigi P; Alpers MP; Wegmüller B; Zellmeyer M; Fürer E; Que JU; Herzog C
    P N G Med J; 2001; 44(1-2):6-16. PubMed ID: 12418673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
    Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
    Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.
    Punjabi NH; Richie EL; Simanjuntak CH; Harjanto SJ; Wangsasaputra F; Arjoso S; Rofiq A; Prijanto M; Julitasari ; Yela U; Herzog C; Cryz SJ
    Vaccine; 2006 Mar; 24(11):1776-85. PubMed ID: 16303216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
    Huebner RE; Nicol M; Mothupi R; Käyhty H; Mbelle N; Khomo E; Klugman KP
    Vaccine; 2004 Dec; 23(6):802-6. PubMed ID: 15542205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine.
    Kurikka S; Käyhty H; Peltola H; Saarinen L; Eskola J; Mäkelä PH
    Pediatrics; 1995 Jun; 95(6):815-22. PubMed ID: 7761204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization of children with sickle cell disease with Haemophilus influenzae type b polysaccharide vaccine.
    Rubin LG; Voulalas D; Carmody L
    Pediatrics; 1989 Sep; 84(3):509-13. PubMed ID: 2788866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period.
    Miller MA; Meschievitz CK; Ballanco GA; Daum RS
    Pediatrics; 1995 Apr; 95(4):522-7. PubMed ID: 7700752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid?
    Scheifele D; Barreto L; Meekison W; Guasparini R; Friesen B
    CMAJ; 1993 Oct; 149(8):1105-12. PubMed ID: 8221449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of Haemophilus influenzae type B vaccine given in combination with DTwP at 6, 10 and 14 weeks of age.
    Cherian T; Thomas N; Raghupathy P; Durot I; Dutta A
    Indian Pediatr; 2002 May; 39(5):427-36. PubMed ID: 12037271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, in healthy adult volunteers.
    Kim N; Choi G; Lim CY; Lee JW; Kim KH; Lee HJ
    Arch Pharm Res; 2010 Jun; 33(6):919-24. PubMed ID: 20607497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
    Kaplan SL; Duckett T; Mahoney DH; Kennedy LL; Dukes CM; Schaffer DM; Mason EO
    J Pediatr; 1992 Mar; 120(3):367-70. PubMed ID: 1538281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population.
    Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM
    J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine.
    Nolan T; Altmann A; Skeljo M; Streeton C; Schuerman L
    Vaccine; 2004 Nov; 23(1):14-20. PubMed ID: 15519702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
    Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
    Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.